# TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nsclc-3/  
OnCo record `nsclc-3` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TGRX-326 in non-small-cell lung cancer, active and no longer recruiting.

## Summary

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06082635, led by Shenzhen TargetRx with Sun Yat-Sen University Cancer Center, and active but no longer recruiting on the registry. Official title: A Multi-centered, Randomised, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 321 participants (actual). The study started in 2023-12-14 and primary completion is expected in 2026-04-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06082635
- Phase: 3
- Setting: A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Shenzhen TargetRx
- Enrolled: 321

## Sources

- ClinicalTrials.gov NCT06082635: https://clinicaltrials.gov/study/NCT06082635

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [TGRX-326](https://onco.cc/drugs/tgrx-326/)
- companies: [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/)

---
JSON: https://onco.cc/api/v1/entities/nsclc-3.json